Budget Impact Analysis of the use of emicizumab for bleeding prophylaxis in patients with Hemophilia A with inhibitors in the Brazilian Health System

• Main Authors: Nicolas Segre (Author), Verónica Elizabeth Malta (Author), Tamiê de Camargo Martins (Author)
• Formato: Livro
• Publicado em: Instituto Nacional de Assistência Farmacêutica e Farmacoeconomia, 2022-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Hemophilia A is a hereditary hemorrhagic disorder characterized by deficiency or dysfunction of the coagulation protein factor VIII. The standard therapy consists of factor VIII replacement, which can lead to the development of neutralizing antibodies (inhibitors), a major complication that implies...